CLINICAL TRIALS PROFILE FOR KANAMYCIN

All Clinical Trials for Kanamycin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004689 ↗	Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease	Completed	National Jewish Health	Phase 2	1991-01-01	OBJECTIVES: I. Determine the bacteriological activity of amithiozone against Mycobacterium avium complex (MAC) pulmonary disease. II. Define the ability of amithiozone to improve clinical outcomes in patients with MAC infection. III. Determine the safety and tolerance of amithiozone with chronic dosing in these patients. IV. Assess the contribution of clarithromycin, streptomycin, rifampin, ethambutol, kanamycin, and amithiozone in the treatment of pulmonary MAC infection.
NCT00042289 ↗	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)		2003-03-01	The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00042289 ↗	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)		2003-03-01	The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00579956 ↗	A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis	Unknown status	Mahidol University	N/A	2007-12-01	Melioidosis, an infection caused by the bacterium Burkholderia pseudomallei, is a major cause of community-acquired septicaemia in northeast Thailand. Common manifestations include cavitating pneumonia, hepatic and splenic abscesses, and soft tissue and joint infections. Despite improvements in diagnostic procedures and treatment, the mortality of severe melioidosis remains unacceptably high - approximately 35% with currently used antibiotics (ceftazidime or co-amoxiclav). There is clear evidence that antibiotics can affect mortality; the use of ceftazidime rather than previous regimens (doxycycline + chloramphenicol + co-trimoxazole) led to a 50% reduction in mortality from 80% to 35%. However, the mortality in the first 48 hours has not been altered by any treatment regimen. A key question is whether alternative antibiotics could improve early outcome. The hypothesis tested is that meropenem is superior to ceftazidime in terms of mortality for the treatment of melioidosis.

Clinical Trial Conditions for Kanamycin

Condition Name

Condition Name for Kanamycin
Intervention	Trials
Tuberculosis	3
Multidrug Resistant Tuberculosis	2
MDR-TB	1
Meconium Ileus	1

Condition MeSH

Condition MeSH for Kanamycin
Intervention	Trials
Tuberculosis	8
Tuberculosis, Multidrug-Resistant	5
Mycobacterium Infections	2
Infections	1

Clinical Trial Locations for Kanamycin

Trials by Country

Trials by Country for Kanamycin
Location	Trials
United States	21
Thailand	7
South Africa	6
Brazil	4
Korea, Republic of	3

Trials by US State

Trials by US State for Kanamycin
Location	Trials
Florida	1
District of Columbia	1
Connecticut	1
Colorado	1
California	1

Clinical Trial Progress for Kanamycin

Clinical Trial Phase

Clinical Trial Phase for Kanamycin
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Kanamycin
Clinical Trial Phase	Trials
Completed	5
Unknown status	3
Active, not recruiting	1

Clinical Trial Sponsors for Kanamycin

Sponsor Name

Sponsor Name for Kanamycin
Sponsor	Trials
Janssen Infectious Diseases BVBA	2
National Institute of Allergy and Infectious Diseases (NIAID)	2
Novartis Institute for Tropical Medicine	1

Sponsor Type

Sponsor Type for Kanamycin
Sponsor	Trials
Other	27
NIH	3
Industry	2

Kanamycin: Clinical Trials Update, Market Analysis, and Projections

Introduction

Kanamycin, an aminoglycoside antibiotic, has been a staple in the treatment of various bacterial infections, including tuberculosis. However, its use has been evolving due to concerns over toxicity and the emergence of more effective alternatives. Here, we will delve into the current clinical trials landscape, market analysis, and future projections for kanamycin.

Clinical Trials and Usage Updates

Replacement by Amikacin in MDR-TB Regimens

The World Health Organization (WHO) has recommended replacing kanamycin with amikacin in the treatment of multidrug-resistant tuberculosis (MDR-TB) due to its better safety profile and efficacy. This shift is part of the updated guidelines that emphasize the use of all-oral regimens and the reduction of injectable agents like kanamycin and capreomycin[3].

Current Clinical Practices

While kanamycin is still used in some MDR-TB regimens, its use is strictly monitored, and audiometry is mandatory to check for ototoxicity. The WHO advises against changing a patient's regimen unless a better alternative is available, such as replacing kanamycin with amikacin[3].

Market Analysis

Global Market Size and Forecast

The global market for kanamycin sulfate API was estimated to be worth $190 million in 2023. It is forecasted to grow to $247.8 million by 2030, with a compound annual growth rate (CAGR) of 3.9% during the period from 2024 to 2030[2].

Key Players

The market is dominated by several key players, including LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTD, Fujian Fukang Pharmaceutical, Chengdu Brilliant Pharmaceutical, and Zhejiang Hisun Pharmaceutical. These companies play a significant role in the production and distribution of kanamycin sulfate API[2].

Market Segmentation

The market is segmented by type, application, and region. The segmentation helps in understanding the diverse uses of kanamycin, such as in the treatment of tuberculosis and other bacterial infections, as well as its application in veterinary medicine[5].

Market Projections

Growth Factors and Trends

The growth of the kanamycin market is influenced by several factors, including the increasing incidence of bacterial infections, the need for effective antibiotics, and advancements in pharmaceutical manufacturing. However, the market is also constrained by the emergence of more effective and safer alternatives, such as amikacin, and the stringent regulatory environment[5].

Production and Consumption Forecast

From 2024 to 2029, the global and Chinese production and consumption of kanamycin are expected to show a steady growth trend. The production value and capacity are projected to increase, driven by the demand from various applications. The market share and supply and consumption dynamics are also expected to evolve, reflecting the changing landscape of antibiotic usage[5].

Economic Impact

The global and Chinese macroeconomic environments play a crucial role in the kanamycin market. Economic stability and growth in these regions can positively impact the demand for kanamycin, while economic downturns can reduce consumption. The market is also influenced by operational research and data collection, which help in informing future updates to treatment guidelines[5].

Challenges and Opportunities

Challenges

One of the significant challenges facing the kanamycin market is the potential for toxicity, particularly ototoxicity and nephrotoxicity. This has led to a decline in its use in favor of safer alternatives. Additionally, the market is highly competitive, and regulatory changes can significantly impact the demand for kanamycin[3][5].

Opportunities

Despite the challenges, there are opportunities for growth in niche markets where kanamycin remains an effective treatment option. Innovations in formulation and delivery methods could also revitalize the market. Moreover, the ongoing need for effective antibiotics in developing countries presents a potential market for kanamycin[5].

Key Takeaways

• Clinical Trials and Usage: Kanamycin is being replaced by amikacin in MDR-TB regimens due to safety concerns.
• Market Size and Forecast: The global kanamycin sulfate API market is projected to grow to $247.8 million by 2030.
• Key Players: The market is dominated by several pharmaceutical companies, including LIVZON GROUP and Fujian Fukang Pharmaceutical.
• Growth Factors and Trends: The market is influenced by the increasing incidence of bacterial infections and the emergence of safer alternatives.
• Challenges and Opportunities: The market faces challenges due to toxicity concerns but has opportunities in niche markets and developing countries.

FAQs

What are the current recommendations for using kanamycin in MDR-TB treatment?

Kanamycin is being systematically replaced by amikacin in MDR-TB regimens due to its better safety profile and efficacy. However, if kanamycin is still in use, it must be monitored closely for toxicity[3].

What is the projected market size of kanamycin sulfate API by 2030?

The global market for kanamycin sulfate API is forecasted to grow to $247.8 million by 2030, with a CAGR of 3.9% from 2024 to 2030[2].

Who are the key players in the kanamycin market?

The key players include LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTD, Fujian Fukang Pharmaceutical, Chengdu Brilliant Pharmaceutical, and Zhejiang Hisun Pharmaceutical[2].

What are the main challenges facing the kanamycin market?

The main challenges include the potential for toxicity, particularly ototoxicity and nephrotoxicity, and the emergence of safer and more effective alternatives like amikacin[3][5].

Are there any opportunities for growth in the kanamycin market?

Yes, there are opportunities in niche markets where kanamycin remains an effective treatment option, and in developing countries where there is an ongoing need for effective antibiotics[5].

How does the global macroeconomic environment impact the kanamycin market?

The global and Chinese macroeconomic environments can positively or negatively impact the demand for kanamycin. Economic stability can increase demand, while economic downturns can reduce consumption[5].